Dr. Troy H. Guthrie, Jr.

  • MD
  • Medical Oncologist
  • Spoken languages English

Overview

Career Positions

Current position(s)

  • GenesisCare of Jacksonville, Medical Oncology Division - Medical Oncologist, Jacksonville, FL

Past position(s)

  • Baptist Cancer Institute - Director of Research and Education, Jacksonville, FL
  • University of Florida Health Science Center - Professor of Medicine & Cancer Committee, Jacksonville, FL
  • Baptist Cancer Institute - Director of Research and Education, Jacksonville, FL

Education

Universities

  • University of Georgia, Bachelor's of Science, Zoology and Biology, Athens, GA
  • Medical College of Georgia, Doctor of Medicine, Augusta, GA

Residencies

  • University of Texas Health Science Center San Antonio, Internal Medicine and Hematology, San Antonio, TX

Internships

  • University of Texas Health Science Center San Antonio, San Antonio, TX

Fellowships

  • Medical College of Georgia, Hematology and Oncology, Augusta, GA
  • Hematology and Oncology, Augusta, GA

Expertise And Interests

Interests

  • Breast, Lung, Gastrointestinal and Prostate Cancer, Sickle Cell Anemia, Lymphoma, Melanoma, Renal Cell Carcinoma, and a strong interest on clinical research for state-of-the-art therapy

Accomplishments

Publications

  • Isolated leptomeningeal progression from sinonasal carcinomas: Implications for staging workup and treatment.

Clinical studies

The study will collect data primarily from oncology care facilities in Australia, the EU,Switzerland, and the US. Electronic case report forms will be used by study investigators orqualified research staff members to enter data. As part of the routine care, study investigatorswill evaluate or ask patients about their disease history, treatment history, and any AEexperienced at the time of patient enrollment and during the study period. If an SAE is treatedoutside of the study sites, the information about the SAE, management, and outcomes will beobtained by study investigators or study staff from the healthcare facilities where patients’ SAEsare treated and managed in compliance with country regulations for human research ethics andprivacy.> Treatment with commercial Nivolumab for the 1st time (alone or with ipilimumab)> Observational registry study which requires no extra visits.

View Study